# **Krebs Biochemicals & Industries Limited**



CIN: L24110AP1991PLC103912

9th February 2017

To, The Manager, Department of Corporate Relations, BSE Limited, P J Towers, Dalal Street, Fort, Mumbai- 400001. To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

## Sub: Outcome of Board Meeting held on 9th February 2017.

We refer to the above mentioned subject, we herewith intimate the Exchange, and that the Board of Directors at their meeting held on 9<sup>th</sup> February 2017 has considered and approved interalia the following items of business:

1. Unaudited Financial results and the Limited Review Report for the quarter ended 31<sup>st</sup> December 2016, enclosed herewith.

This is for the information and records of the Exchange, Please.

Kindly note that the board meeting commenced at 01:00 PM and concluded at 4:30 PM

Thanking You,

Yours Faithfully als & Industries Limited

Haritha Varanasi Company Secretary

Encl. As above

Regd. Office : Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Corporate Office : 8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034 Tel : 040-66808040 E-mail : marketing@krebsbiochem.com Website : www.krebsbiochem.com

KREBS BIOCHEMICALS & INDUSTRIES LIMITED CIN:L24110AP1991PLC103912 Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031 Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

### STAND ALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2016

	Particulars		Quarter Ended		Nine Months Ended		Previous Year Ended				
		31.12.2016 (Unaudited)	30.09.2016 (Unaudited)	31.12.2015 (Unaudited)	31.12.2016 (Unaudited)	31.12.201 5 (Unaudited)	31.03.2016 (Unaudited)				
	PART - 1				( ) = minutes (	(cardine d)	(chuddhed)				
l	Income from Operations										
_	a) Net Sales / Income from Operations	1.45			8.58	17. 79	17,79				
	b) Other Operating Income	39.00	39.00	45.16	117.00	84.16	123.17				
2	Total Income from operations (net) Expenses	40.45	39.00	45.16	125.58	101_95	140.96				
-	a. Cost of Material Consumed	0.03	0.69	(0.40)	0.02	175 (1	100.0				
	b. Changes in inventories of finished goods,	0.03	0,09	(8.48)	0.83	175.64	177.26				
	work-in-progress and stock -in-trade	1.47	(6,39)	18.85	(0.85)	(227,98)	(162.69				
	c. Employee benefits expense	141.88	149.36	120.83	415.18	368.44	566,52				
	d. Depreciation and Amortisation expense	104.09	104.09	95.54	312.28	286.62	448.62				
	e. Other Manufacturing Expenses	91.23	65.41	82.70	227.93	356.66	449.13				
	f. Other Expenses	68.99	80.88	65.21	206.46	241.75	350.97				
	Total Expenses	407.69	394.04	374.65	1,161.82	1,201.13	1,829.81				
5	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1 - 2)	(367.24)	(355.04)	(329.49)	(1,036.24)	(1,099.18)	(1,688.85				
	Other Income	3.70	1.75	2.63	6.58	71.48	102.94				
	Profit / (Loss) from ordinary activities before finance costs $(3 \pm 4)$	(363,54)	(353.29)	(326.86)	(1,029.65)	(1,027.70)	(1,585.91				
5	Finance Costs	87.35	69.70	20,90	207.72	25.17	73.88				
,	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items $(5 \pm 6)$	(450.89)	(422.99)	(347.76)	(1,237.37)	(1,052.87)	(1,659.79				
	Exceptional Items:										
	a) Debit balances written off	-		-			(0.03				
-	b) Diminition in Value of Inventory	(4.04)			(14.20)	(12( 02)	(0.93				
	c) Amounts Written Back		(1.88)		(14.29)	(126.93)	(126.93				
		4.33	1.41	19,56	5,74	89.66	96.49				
	d) Profit on Sale of Food Division's Immovable Assets	-	5 <b>-</b> 3			59.12	59.12				
	e) Prior period Income	( <del>*</del> )	7.46		7.46		1/#				
	f) Prior period Expenditure	(1.00)	1.183	(e)	(1.00)	-	7 <b>.</b>				
•	Profit / (Loss) from ordinary activities before Tax (7 ± 8)	(451.60)	(415.99)	(328.20)	(1,239.45)	(1,031.02)	(1,632.04				
)	Tax Expense	-				÷	0.00				
l	Net Profit / (Loss) after Tax (9 ± 10)	(451.60)	(415,99)	(328.20)	(1,239.45)	(1,031.02)	(1,632.04				
2	Extra Ordinary Items	-		( <b>1</b> 4)		<u>i</u>					
3	Net Profit / (Loss) for the period $(11 \pm 12)$	(451.60)	(415.99)	(328.20)	(1,239,45)	(1,031.02)	(1,632.04				
	Other Comprehensive Income	=	( <b>-</b> 1)	() <b>-</b> ()		÷					
	Total Comprehensive Income after Tax(13 ± 14)										
	(Comprising Profit (Loss) and other Comprehensive Income for the period)	(451.60)	(415.99)	(328.20)	(1,239.45)	(1,031.02)	(1,632.04				
	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1374.43	1,374.43	1,306.43	1374.43	1,306.43	1,306.43				
	Reserve Excluding Revaluation Reserves as per Balance Sheet of	-	-			1,500.45	(372.26				
	previous Accounting Year Earning Per Share (before extraordinary Items) (of Rs.10/- each) (not						(372.20				
i)	Annualised)										
	(a) Basic	(3.29)	(3.03)	(2.51)	(9.02)	(7.89)	(13.24				
	(b) Diluted	(3.29)	(3.03)	(2.51)	(9.11)	(7.89)	(12.54				
i)	Earning Per Share (after extraordinary Items) (of Rs.10/- each) (not										
-	Annualised)										
	(a) Basic	(3.29)	(3.03)	(2.51)	(9.02)	(7.89)	(13.24				
	b) Diluted (3.29) (3.03) (2.51) (9.11) (7.89) (12.54) he above results have been reviewed by the Audit Committee at its meeting held on 09th February, 2017 and approved by the Board of Directors of the Company at its neeting held on 09th February, 2017. The results were subjected to limited review by Statutory Auditors.										
	The Company is operating in one segment only hence no segment results ha										
	Figures have been regrouped, rearranged wherever necessary.										
	The Company has adopted Ind-As with effect from 1st April 2016 with comparitives being restated. Accordingly the impact of transition has been provided in the Opening eserves as at 1st April 2015 and all the periods presented have been restated accordingly.										
	Results for the quarter / nine months ended 31st December 2016 are in compliance with Indian Accounting Standards (Ind-As) notified by the Ministry of Corporate Affairs Consequently, result for the quarter ended 31st December 2015, nine months ended 31st December 2015 and previous year ended 31st March 2016 have been restared to comply with Ind-As to make them comparable.										
	TE 4					MANNA	E Contraction				
	Hyderabad				V	JE II	Avinash Ray				
	09.02.2017				F.	£	to mash iter				

#### KREBS BIOCHEMICALS & INDUSTRIES LIMITED RECONCILATION OF PROFIT AND RESERVE BETWEEN INDAS AND PREVIOUS INDIAN GAAP FOR EARLIER PERIOD AND AS AT MARCH 31, 2016

			11			Rs.in lakhs	
	Nature of adjustments		Profit reconciliation			Reserve reconciliation	
SI #		Note ref.	Quarter ended 31st Dec 2015		Year ended 31st March 2016	As at 31st March 2016	
	Net Profit / Reserves as per Previous Indian						
	GAAP		(328.20)	(1,031.02)	(1,632.04)	(1,477.97)	
	Fair valuation as deemed cost for Property, Plant			,, ,			
1	and Equipment	1		-	-	4,743.25	
2	Fair valuation of Intangible Assets	2	-		2-1	(379.28)	
3	Fair Valuation of for Financial Assets	3			-	(3,126.96)	
4	Defered Tax	4	122	14		(131.30)	
	Sub Total		-	-	14	1,105.71	
	Net profit/ Reserves as per Ind As		(328.20)	(1,031.02)	(1,632.04)	(372.26)	

#### Notes:

#### 1 Fair valution as deemed cost for Property, Plant and Equipment

Considered fair value for property, viz land admeasuring 110.7 acres, situated in Andhra Pradesh in India, with impact of Rs.4743.25 lakhs in accordance with stipulations of IND AS 101 (see IND AS 16) with the resultant impact being accounted for in the reserves.

#### 2 Fair Valuation of Intangible Assets

Considered fair value of Intangible Assets based on expected future economic benefits using reasonable and supportable assumptions in accordance with stipulations of IND AS 38 with the resultant impact being accounted for in the reserves.

#### 3 Fair valuation for Financial Assets

The Company has valued financial assets at fair value. Impact of fair value changes as on the date of transition, is recognised in opening reserves and changes thereafter are recongnised in Profit and Loss Account or Other Comprehensive Income, as the case may be.

4 Defered Tax

The Impact of transition adjustments together with IND AS mandate of using balance sheet approach (against profit and loss approach in the previous GAAP) for computation of deferred taxes has resulted in charge to the Reserves, on the date of transition, with consequential impact to the Profit and Loss account for the subsequent periods.

5 The Audit Committee has reviewed the above results and the Board of Directors has approved the above results

and its release at their resepective meetings held on 09th February, 2017. The Statutory Auditors of the

Company have carried out a Limited Review of the results for the current quarter.

inash Rav Managing Director DIN: 01616152

Place: Hyderabad Date: 09.02.2017



PAVULURI & Co.

CHARTERED ACCOUNTANTS # 105, 1st Block, 1st Floor, Divya Shakti Complex, Ameerpet, Hyderabad - 500 016. Ph : 040 - 2373 1837, 4025 8691 Fax : 040 - 2374 8729 Email : pavuluriandco@gmail.com pavuluriandco@hotmail.com

#### Review Report to the Board of Directors of KREBS BIO-CHEMICALS & INDUSTRIES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **M/s. KREBS BIO-CHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter **31**<sup>st</sup> **December, 2016**pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November 2015 and CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended **31st December**, **2016**prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015,read with circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

> For PAVULURI & Co. Chartered Accountants Firm Regn. No: 012194S

(CA. N. RAJESH) PARTNER M.No: 223169

Place: Hyderabad Date: 09.02.2017

Branches :